This finding aligns with the observations of Foudah and colleagues, who reported that the oral administration of RVT in rats with scopolamine-induced memory impairment improved cognitive function by the selective suppression of AChE activity in the hippocampus [16]. The gene discussed is ACHE; the disease is memory impairment.